Author:
HILLARP A.,BAGHAEI F.,FAGERBERG BLIXTER I.,GUSTAFSSON K. M.,STIGENDAL L.,STEN-LINDER M.,STRANDBERG K.,LINDAHL T. L.
Reference17 articles.
1. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboemblic disease: focus on rivaroxaban;Morell;J Clin Pathol,2010
2. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects;Kubitza;Eur J Clin Pharmacol,2005
3. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects;Kubitza;Clin Pharmacol Ther,2005
4. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct factor Xa inhibitor;Perzborn;J Thromb Haemost,2005
5. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral direct factor Xa inhibitor - in healthy subjects;Mueck;Int J Clin Pharmacol Ther,2007
Cited by
260 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献